NO922851L - Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose - Google Patents

Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose

Info

Publication number
NO922851L
NO922851L NO92922851A NO922851A NO922851L NO 922851 L NO922851 L NO 922851L NO 92922851 A NO92922851 A NO 92922851A NO 922851 A NO922851 A NO 922851A NO 922851 L NO922851 L NO 922851L
Authority
NO
Norway
Prior art keywords
rog
osteporose
trifluormethyl
treatment
rhver
Prior art date
Application number
NO92922851A
Other languages
English (en)
Other versions
NO922851D0 (no
Inventor
Charles Schwender
Keith Demarest
David Wustrow
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NO922851D0 publication Critical patent/NO922851D0/no
Publication of NO922851L publication Critical patent/NO922851L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nye benzylfosfonatforbindelser med den generelle formel:. hvor Ri og Rer like eller forskjellige og er valgt fra hvilke som helst av hydrogen, alkyl, alkenyl, hydroksyalkyl, alksoksyalkyl, aralkyl, aryl eller aminoalkyl;. Rog Rhver kan være enten H eller CF, forutsatt at kun en av Reller Rkan være CFpå samme tid;. Rog Rhver kan være H eller CF, forutsatt at dersom en eller begge av Rog Rer CFså kan hverken Reller Rvære CF, videre forutsatt at R-Rhver ikke kan være H på samme tid, og ytterligere forutsatt at Rog Rhegge kan være etyl kun når Rog R(, hver er CF;. og farmasøytisk akseptable salter derav.
NO92922851A 1991-07-18 1992-07-17 Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose NO922851L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/732,267 US5300687A (en) 1991-07-18 1991-07-18 Trifluoromethylbenzylphosphonates useful in treating osteoporosis

Publications (2)

Publication Number Publication Date
NO922851D0 NO922851D0 (no) 1992-07-17
NO922851L true NO922851L (no) 1993-01-19

Family

ID=24942866

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92922851A NO922851L (no) 1991-07-18 1992-07-17 Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose

Country Status (14)

Country Link
US (2) US5300687A (no)
EP (1) EP0524023A1 (no)
JP (1) JPH05213977A (no)
KR (1) KR930002364A (no)
CN (1) CN1070408A (no)
AU (1) AU657146B2 (no)
CA (1) CA2074020A1 (no)
FI (1) FI923289A (no)
HU (1) HUT62907A (no)
IE (1) IE922341A1 (no)
MX (1) MX9204229A (no)
NO (1) NO922851L (no)
TW (1) TW216796B (no)
ZA (1) ZA925391B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
ZA941088B (en) * 1993-02-19 1995-09-27 Symphar Sa Substituted ketophosphonates the processes for their preparation and pharmaceutical compositions containing them
EP0625522B1 (en) * 1993-05-18 1998-08-19 Takeda Chemical Industries, Ltd. Benzopyran derivatives and their use
ATE199721T1 (de) * 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd Phosphonsäure verbindungen imre herstellung und verwendung
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
EP0906759A1 (de) 1997-10-02 1999-04-07 Roche Diagnostics GmbH Neue Osteoblastenspezifische Mitogene: Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6911553B1 (en) 1997-10-02 2005-06-28 Roche Diagnostics Gmbh Osteoblast-specific mitogens and drugs containing such compounds
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
AU1525700A (en) 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US20020150887A1 (en) * 2000-11-09 2002-10-17 National Institute Of Advanced Industrial Science And Technology Methods and nucleic acid probes for molecular genetic analysis of polluted environments and environmental samples
US20050032060A1 (en) * 2001-08-31 2005-02-10 Shishir Shah Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US7335470B2 (en) 2001-10-12 2008-02-26 Perkinelmer, Las, Inc. Compilations of nucleic acids and arrays and methods of using them
US7439346B2 (en) * 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
US6916621B2 (en) * 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2006025995A2 (en) * 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions and methods using md-2 mutants and chimeric proteins
CN1302001C (zh) * 2005-01-20 2007-02-28 申厚宝 邻氯苄基膦酸二甲酯生产工艺
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
US20100221345A1 (en) 2006-01-18 2010-09-02 National University Corporation Tokyo Medical And Osteogenic biomaterial containing osteogenesis promoting substance and nanogel
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
US8993542B2 (en) * 2008-01-25 2015-03-31 Chimerix Inc. Methods of treating viral infections
CN102099941A (zh) 2008-07-18 2011-06-15 乔治亚州技术研究公司 用于有机电子器件的具有改变功函数的稳定电极以及方法
WO2010019696A2 (en) 2008-08-12 2010-02-18 Allylix, Inc. Method for production of isoprenoids
CA2734922C (en) 2008-09-15 2020-01-14 Laetitia Malphettes Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
JP5350733B2 (ja) * 2008-09-30 2013-11-27 株式会社クレハ ホスホン酸、ホスホン酸銅化合物、樹脂組成物及び積層体
EP2417142B1 (en) 2009-04-06 2014-07-23 Georgia Tech Research Corporation Electronic devices comprising novel phosphonic acid surface modifiers
US7960456B2 (en) * 2009-05-27 2011-06-14 Bromine Compounds Ltd. Halogenated phosphonates, processes for their preparation and their use as flame retardants
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US20120164104A1 (en) 2009-08-03 2012-06-28 Chimerix, Inc. Composition and Methods of Treating Viral Infections and Viral Induced Tumors
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
AU2011248620B2 (en) 2010-04-26 2015-11-26 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP4174077A1 (en) * 2021-10-27 2023-05-03 Merck Patent GmbH Electronic switching device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917533A (en) * 1954-05-12 1959-12-15 Virginia Carolina Chem Corp Dialkylaminoalkyl esters of phosphonic acid and method of preparing same
US3363032A (en) * 1964-06-11 1968-01-09 Monsanto Co Long chain aliphatic benzylphosphonic acids, esters and salts
DE3339383A1 (de) * 1983-10-29 1985-05-09 Bayer Ag, 5090 Leverkusen Distyrylverbindungen
US4822780A (en) * 1987-07-08 1989-04-18 Otsuka Pharmaceutical Factory, Inc. Carboxamide compounds
DE4003054A1 (de) * 1990-02-02 1991-08-08 Hoechst Ag Verwendung von benzylphosphonsaeurederivaten zur behandlung von durch viren verursachte krankheiten
US5300687A (en) * 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis

Also Published As

Publication number Publication date
EP0524023A1 (en) 1993-01-20
AU1965692A (en) 1993-01-21
NO922851D0 (no) 1992-07-17
HUT62907A (en) 1993-06-28
CN1070408A (zh) 1993-03-31
US5300687A (en) 1994-04-05
FI923289A (fi) 1993-01-19
JPH05213977A (ja) 1993-08-24
TW216796B (no) 1993-12-01
US5532226A (en) 1996-07-02
ZA925391B (en) 1994-01-17
IE922341A1 (en) 1993-01-27
CA2074020A1 (en) 1993-01-19
KR930002364A (ko) 1993-02-23
AU657146B2 (en) 1995-03-02
MX9204229A (es) 1993-04-01
HU9202353D0 (en) 1992-10-28
FI923289A0 (fi) 1992-07-17

Similar Documents

Publication Publication Date Title
NO922851L (no) Trifluormetylbenzylfosfonater som er nyttig for behandling av osteporose
UA42684C2 (uk) Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі
NO954427L (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
MY101208A (en) Phenyl-piperazine anti-arrhythmia agents.
MY108885A (en) Heterocyclic-cyclic amine derivatives.
NO922147L (no) Heterocykliske derivater
MY121967A (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
DK0736018T3 (da) 4,5-Diaryloxazolderivater
NO922949L (no) Forbindelser og fremgangsmaater for inhibering av hiv- og beslektede virus
MX9701685A (es) Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
ATE283268T1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
HK21595A (en) Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders
ES2108595A1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
FR2672213B1 (fr) Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO982927L (no) Biologisk aktive benzotiazolon etanaminer
NO915021D0 (no) Nye metylenbisfosfonsyrederivater
ES2104509A1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
DE69813554D1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer
NO922151L (no) Gingerol og gingerdiolderivater som hypokolesterolemiske og antiatherosklerotiske midler
NO983283L (no) Hydrokamsyre-baserte Kollagenase-inhibitorer
FR2726271B1 (fr) Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
NO933170L (no) Heterocykliske forbindelser
ES8506002A1 (es) Procedimiento para la obtencion de 2-(1-indolinil-metil)-imidazolinas